Vaglio Augusto, Maritati Federica
Nephrology Unit, University Hospital, Parma, Italy
Nephrology Unit, University Hospital, Parma, Italy.
J Am Soc Nephrol. 2016 Jul;27(7):1880-9. doi: 10.1681/ASN.2015101110. Epub 2016 Feb 9.
Idiopathic retroperitoneal fibrosis (RPF), reviewed herein, is a rare fibro-inflammatory disease that develops around the abdominal aorta and the iliac arteries, and spreads into the adjacent retroperitoneum, where it frequently causes ureteral obstruction and renal failure. The clinical phenotype of RPF is complex, because it can be associated with fibro-inflammatory disorders involving other organs, is considered part of the spectrum of IgG4-related disease, and often arises in patients with other autoimmune conditions. Obstructive uropathy is the most common complication, although other types of renal involvement may occur, including stenosis of the renal arteries and veins, renal atrophy, and different types of associated GN. Environmental and genetic factors contribute to disease susceptibility, whereas the immunopathogenesis of RPF is mediated by different immune cell types that eventually promote fibroblast activation. The diagnosis is made on the basis of computed tomography or magnetic resonance imaging, and positron emission tomography is a useful tool in disease staging and follow-up. Treatment of idiopathic RPF aims at relieving ureteral obstruction and inducing disease regression, and includes the use of glucocorticoids, combined or not with other traditional immunosuppressants. However, biologic therapies such as the B cell-depleting agent rituximab are emerging as potentially efficacious agents in difficult-to-treat cases.
本文所综述的特发性腹膜后纤维化(RPF)是一种罕见的纤维炎性疾病,发生于腹主动脉和髂动脉周围,并蔓延至邻近的腹膜后间隙,常导致输尿管梗阻和肾衰竭。RPF的临床表型复杂,因为它可能与累及其他器官的纤维炎性疾病相关,被认为是IgG4相关疾病谱的一部分,且常发生于患有其他自身免疫性疾病的患者。梗阻性尿路病是最常见的并发症,不过也可能出现其他类型的肾脏受累情况,包括肾动脉和肾静脉狭窄、肾萎缩以及不同类型的相关肾小球肾炎。环境和遗传因素会导致疾病易感性,而RPF的免疫发病机制由不同免疫细胞类型介导,最终促进成纤维细胞活化。诊断基于计算机断层扫描或磁共振成像,正电子发射断层扫描在疾病分期和随访中是一种有用的工具。特发性RPF的治疗旨在缓解输尿管梗阻并促使疾病消退,包括使用糖皮质激素,可联合或不联合其他传统免疫抑制剂。然而,诸如B细胞耗竭剂利妥昔单抗等生物疗法在难治性病例中正在成为潜在的有效药物。